5 Top Trends in Chinese Healthcare & Biopharma in 2020
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being discovered in China around the beginning…
Tagged with IPO
China Biopharma Dealmaking 2020 Review
While many parts of the world ground to a halt as they tried to deal with the global pandemic, China had more or less brought the situation under…
2020’s Top 7 Biotech IPOs in Profile
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech…
China: 2020’s Biggest Biotech IPO in Profile
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling…
HKEX SVP Reflects on Two Years of Pre-Revenue Biotech IPO…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as…
Hong Kong Biotech IPOs since Listing Reform in April 2018
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech…
China Pharma News Roundup July 24th 2020
A roundup of latest news from Chinese pharma and biotech, including a record high share price for Hansoh, strategic healthcare partnerships, venture…
SCM Lifescience: A Global Approach to Korean Regenerative…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in…
Michael Chan – Senior Vice President, Global Issuer…
Michael Chan, Senior Vice President of Global Issuer Services for the Hong Kong Exchange (HKEX) highlights the vibrancy and diversity that biotechs…
Xu Ting – Founder, Chairman & CEO, Alphamab Oncology,…
PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their…
5 Cell & Gene Companies to Watch in South Korea
South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to…
Jingsong Wang – Chairman & CEO, Harbour BioMed, China
PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of…
